<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18637">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02864264</url>
  </required_header>
  <id_info>
    <org_study_id>IM012-004</org_study_id>
    <secondary_id>2016-000895-72</secondary_id>
    <nct_id>NCT02864264</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis</brief_title>
  <official_title>Double-Blind, Randomized, Placebo-Controlled, Single Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Target Engagement of BMS-986184 in Healthy Subjects and to Evaluate the Safety, Efficacy, Pharmacokinetics, Target Engagement, and Pharmacodynamics of BMS-986184 in Patients With Moderate to Severe Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine if single and multiple doses of BMS-986184
      are safe and well tolerated in healthy male and female subjects. The primary purpose of the
      proof of mechanism study is to determine safety and efficacy in patients with ulcerative
      colitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of safety and tolerability of BMS-986184 as assessed by vital sign measurements</measure>
    <time_frame>Up to 177 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of safety and tolerability of BMS-986184 as assessed by physical examination findings</measure>
    <time_frame>Up to 177 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of safety and tolerability of BMS-986184 as assessed by clinical laboratory test results</measure>
    <time_frame>Up to 177 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of safety and tolerability of BMS-986184 as assessed by Electrocardiogram (ECG) assessments</measure>
    <time_frame>Up to 177 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of incidence, severity and outcome of all Adverse Events (AEs)</measure>
    <time_frame>Up to 177 days</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD) - IV Panel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous (IV) dose of BMS-986184 or placebo matching BMS-986184</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD) - SC Panel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous (SC) dose of BMS-986184 or placebo matching BMS-986184</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose (MAD) - IV Panel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple IV doses of BMS-986184 or placebo matching BMS-986184</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose (MAD) - SC Panel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple SC doses of BMS-986184 or placebo matching BMS-986184</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proof of Mechanism (POM) - IV Panel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple IV doses of BMS-986184 or placebo matching BMS-986184</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proof of Mechanism (POM) - SC Panel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple SC doses of BMS-986184 or placebo matching BMS-986184</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986184</intervention_name>
    <arm_group_label>Single Ascending Dose (SAD) - IV Panel</arm_group_label>
    <arm_group_label>Single Ascending Dose (SAD) - SC Panel</arm_group_label>
    <arm_group_label>Multiple Ascending Dose (MAD) - IV Panel</arm_group_label>
    <arm_group_label>Multiple Ascending Dose (MAD) - SC Panel</arm_group_label>
    <arm_group_label>Proof of Mechanism (POM) - IV Panel</arm_group_label>
    <arm_group_label>Proof of Mechanism (POM) - SC Panel</arm_group_label>
    <other_name>anti - interferon gamma-induced protein 10(IP-10) antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching BMS-986184</intervention_name>
    <arm_group_label>Single Ascending Dose (SAD) - IV Panel</arm_group_label>
    <arm_group_label>Single Ascending Dose (SAD) - SC Panel</arm_group_label>
    <arm_group_label>Multiple Ascending Dose (MAD) - IV Panel</arm_group_label>
    <arm_group_label>Multiple Ascending Dose (MAD) - SC Panel</arm_group_label>
    <arm_group_label>Proof of Mechanism (POM) - IV Panel</arm_group_label>
    <arm_group_label>Proof of Mechanism (POM) - SC Panel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Female subjects must provide documentation of an acceptable method of surgical
             sterilization or meet the protocol criteria for menopause

          -  Male and female healthy participants, as determined by no evidence of organ
             dysfunction or any clinically significant deviation from normal in medical history,
             physical examination, ECGs, and clinical laboratory and procedure determinations
             beyond what is consistent in the target population.

        Exclusion Criteria:

          -  Any bacterial, fungal or viral infection, including tuberculosis, HIV, hepatitis B or
             hepatitis C

          -  Subjects with history of any type of heart disease, heart irregularities, high blood
             pressure, low blood pressure, fainting, ECG abnormalities, or any heart disease from
             childhood

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0004</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chisinau</city>
        <zip>MD-2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bucharest</city>
        <zip>050152</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0003</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Georgia</country>
    <country>Moldova, Republic of</country>
    <country>Romania</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>February 16, 2017</lastchanged_date>
  <firstreceived_date>August 9, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Colitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
